Delving into the Latest Updates on LY-178002 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LY178002, LY-178002

Target

5-LOX x PLA2 x PLA2G2A

Mechanism

5-LOX inhibitors(Arachidonate 5-lipoxygenase inhibitors), PLA2 inhibitors(Phospholipases A2 inhibitors), PLA2G2A inhibitors(Phospholipase A2 group IIA inhibitors)

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication

Arthritis

Inactive Indication

Inflammationischemic brain injury

Originator Organization

Eli Lilly & Co.

Active Organization

Lilly Research Laboratories

Inactive Organization

Eli Lilly & Co.

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC18H25NO2S

InChIKeyBUDGLLLMROWLOB-UHFFFAOYSA-N

CAS Registry107889-32-7

The kinetic resolution of tazofelone (I) has been reported.The resolution of this sulfide was accomplished via enantioselective sulfoxide formation with tert-Bu hydroperoxide in the presence of a chiral tartrate/titanium complex.The resolution was performed on analogs of compound I in order to explore the substrate specificity of the kinetic resolutionThese experiments have shown that the success of the enantioselective oxidation of this sulfide by tert-Bu hydroperoxide is greatly influenced by the nature of the neighboring amide functionality.

01 Nov 1994·Annals of the New York Academy of SciencesQ2 · CROSS-FIELD

Neuroprotection by Antioxidants in Models of Global and Focal Ischemia

Q2 · CROSS-FIELD

Review

Author: Jill A. Panetta ; James A. Clemens

The authors have investigated the effects of several antioxidants for their ability to protect against brain damage in models of transient cerebral ischemia.Their results demonstrate that several antioxidants have dramatic protective effects in models of transient cerebral ischemia.However, merely possessing antioxidant activity alone does not confer neuroprotective activity on a compoundOne or more addnl. properties are required such as the ability to gain access to the cellular compartment where the damage from ROS is taking place.

01 Sep 1994·TETRAHEDRON LETTERS

Synthesis of 4-thiazolidinones from rhodanines by thiocarbonyl removal

Author: Marvin M. Hansen ; Allen R. Harkness

Slow addition of rhodanines to excess zinc dust in acetic acid at reflux gave 4-thiazolidinones.Identification of dimeric byproducts led to development of a procedure to suppress their formation.

100 Deals associated with LY-178002

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthritis	Preclinical	US	Lilly Research Laboratories	01 Jun 1989
Inflammation	Discovery	US	Eli Lilly & Co.	08 Aug 1986
ischemic brain injury	Discovery	US	Eli Lilly & Co.	08 Aug 1986